ASRI Announces Groundbreaking Discovery: Bifunctional 5-HT2A Antagonist and Sodium Channel Blocker Holds Promise for Bipolar Disorder Treatment prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.
Canadian-incorporated companies Cybin, MindMed among those seeking US regulatory OK to treat mental disorders after generating strong results in human trials